JD Bioscience

본문 바로가기
사이트 내 전체검색
닫기

PIPELINE

HomePipelineNASH

Non-alcoholic steatohepatitis (NASH)

Non-alcoholic
steatohepatitis (NASH)

Loomba and Shulman, 2021
Loomba and Shulman, 2021
  • NASH, an advanced form of non-alcoholic fatty liver disease (NAFLD), can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)

  • Genetic factors, environmental factors, and microbiome alterations are mainly involved in disease progression

Loomba and Shulman, 2021
Loomba and Shulman, 2021
  • Experts estimated that 24% of U.S. adults have NAFLD and more than 6.5% of them have NASH (NIH report, 2021). 20~30% of patients with NASH progress to liver fibrosis in 7 years, and 20% of them progress to cirrhosis in two years.

  • However, since no drugs for NASH are commercially available, off-label drug use is the only available treatment option.

Mechanism of action of GM-X

Mechanism of
action of GM-X

Choi and Kim, 2018
Choi and Kim, 2018
  • In a mouse model, high-fat diet (HFD) feeding increased both serotonin (5-hydroxytryptamine, 5-HT) levels in the portal blood and serotonin receptor 2a (5-HT receptor 2a, Htr2a) expression in the cell membranes of hepatocytes

  • Inhibition of gut-derived serotonin synthesis or direct blocking of the 5-HT2a recepto ameliorates hepatic steatosis by suppressing liver Htr2a signaling.

  • 5-HT is also involved in inflammation and fibrosis-related gene expression in the liver and more importantly, the activation of hepatic stellate cells which is directly connected to the progression of liver fibrosis.

  • The Synthesis of an Htr2a antagonist can provide a potent drug candidate for NASH and liver fibrosis

회원로그인

회원가입

사이트 정보

회사명 : 회사명 / 대표 : 대표자명
주소 : OO도 OO시 OO구 OO동 123-45
사업자 등록번호 : 123-45-67890
전화 : 02-123-4567 팩스 : 02-123-4568
통신판매업신고번호 : 제 OO구 - 123호
개인정보관리책임자 : 정보책임자명

  • 게시물이 없습니다.

접속자집계

오늘
47
어제
194
최대
1,191
전체
168,878
Privacy policy

COPYRIGHT(C) 2021 JD BIOSCIENCE INC. ALL RIGHT RESERVED